Boral Capital upgraded Citius Pharmaceuticals (CTXR) to Buy from Hold with a $9 price target. Citius owns 90% of Citius Oncology (CTOR), which is close to commercializing Lymphir, an immunotherapy ...
"I’m more just mad at myself for getting too caught up in the record and not caught up enough in the sprint finish," the ...
Hosted on MSN1mon
Citius Pharma Reports 2024 Financial Results and Business UpdateCitius Pharma ( (CTXR)) has released its Q4 earnings. Here is a breakdown of the information Citius Pharma presented to its investors. Citius Pharmaceuticals, Inc. is a biopharmaceutical company ...
CRANFORD, N.J., Jan. 8, 2025 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to ...
Citius Pharmaceuticals shares are trading lower by 15% during Wednesday's session. The company announced a $3 million registered direct offering. US Stock Futures Slip After Friday's Fall ...
Deseret News on MSN10d
Former BYU runner shatters American half-marathon record“For the second consecutive year, Weini Kelati improved on the American record at the Houston Half Marathon,“ Runner’s World ...
Las acciones de Citius Pharma cotizan y se negocian en la bolsa de valores NASDAQ. ¿Cuál es el símbolo bursátil de Citius Pharma? El símbolo bursátil de Citius Pharma es “CTXR”.
Por su parte, el equipo del CiTIUS, superó a la mayoría situándose en el podio internacional de la inteligencia artificial. Algo que pone de relieve la excelencia de la investigación realizada ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback